Why the study?
Does zerlasiran reduce Lp(a) levels in Japanese patients with elevated Lp(a)?
Does zerlasiran reduce Lp(a) levels in Japanese patients with elevated Lp(a)?
Emerging Lp(a)-lowering therapies such as zerlasiran show promise for potent and sustained Lp(a) reduction, underscoring the need to measure and address this cardiovascular risk factor.
No takes yet. Share an insight, caveat, or question.
Tada et al. (2026) conducted an editorial in Elevated Lp(a) levels. zerlasiran was evaluated on Pharmacokinetics, efficacy (Lp(a) levels), and safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: